CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists and scientific and research professionals involved in basic, translational and clinical cancer research or treatment.
  
  LEARNING OBJECTIVES

  • Evaluate the recent FDA approval of PARP inhibitors for patients with HER2-negative metastatic breast cancer harboring a germline BRCA mutation, and discern how these agents can be appropriately and safely integrated into routine clinical practice.
  • Appreciate available clinical trial data with FDA-approved PARP inhibitors for patients with ovarian cancer in different disease settings, and safely integrate these agents into routine clinical care.
  • Assess the similarities and differences between the commercially available and investigational PARP inhibitors to better understand the resultant activity and toxicities associated with these agents.
  • Appraise available data evaluating olaparib as maintenance therapy for patients with pancreatic cancer with BRCA mutations whose disease has not progressed on first-line platinum-based chemotherapy, and optimally incorporate this FDA-approved treatment strategy into current management algorithms.
  • Review published clinical research findings with PARP inhibitor monotherapy for appropriately selected patients with progressive metastatic castration-resistant prostate cancer, and identify individuals for whom treatment with these agents is appropriate.
  • Recall the design of ongoing clinical trials evaluating novel applications of PARP inhibitors alone or in combination with other systemic approaches (eg, immunotherapy, chemotherapy) for patients with DDR deficiencies, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which include participation in the evaluation components and short post-tests, enables the participant to earn up to 3.5 (audio) and 3.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide sets, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/OncologyTodayAACR20/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/OncologyTodayAACR20/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/OncologyTodayAACR20/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/OncologyTodayAACR20.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Maha Hussain, MD, FACP, FASCO
  Genevieve Teuton Professor of Medicine
  Division of Hematology/Oncology
  Deputy Director
  Robert H Lurie Comprehensive Cancer Center
  Northwestern University Feinberg School of Medicine
  Chicago, Illinois
  
  Consulting or Advisory Role: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc; Honoraria: Astellas, AstraZeneca Egypt, AstraZeneca Singapore, Genentech, a member of the Roche Group, Phillips Gilmore Oncology Communications Inc, Sanofi Genzyme; Patents, Royalties, Other Intellectual Property: American Society of Clinical Oncology; Research Funding: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, PCCTC, Pfizer Inc; Travel, Accommodations, Expenses: Astellas, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Pfizer Inc.
  
  Ursula Matulonis, MD
  Chief, Division of Gynecologic Oncology
  Brock-Wilson Family Chair
  Dana-Farber Cancer Institute
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Novartis; Consulting Agreement: Merck; Contracted Research: FUJIFILM Pharmaceuticals USA Inc, ImmunoGen Inc, Merck, Mersana Therapeutics, SQZ Biotech; Data and Safety Monitoring Board/Committee: Advaxis Inc; Paid Travel: AstraZeneca Pharmaceuticals LP.
  
  Philip A Philip, MD, PhD, FRCP
  Kathryn Cramer Endowed Chair in Cancer Research
  Professor of Oncology and Pharmacology
  Leader, GI and Neuroendocrine Oncology
  Karmanos Cancer Institute
  Wayne State University
  Detroit, Michigan
  
  Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Ipsen Biopharmaceuticals Inc, Merck, Merus BV, Pfizer Inc, QED Therapeutics, Rafael Pharmaceuticals Inc; Consulting Agreements: Blueprint Medicines, Erytech, SynCore Biotechnology Co Ltd, TriSalus Life Sciences; Contracted Research: Astellas, Bayer HealthCare Pharmaceuticals, BeiGene, Bristol-Myers Squibb Company, Celgene Corporation, Five Prime Therapeutics Inc, Forty Seven Inc, Incyte Corporation, Karyopharm Therapeutics, Merck, Merus BV, Novartis, Novocure, QED Therapeutics, Rafael Pharmaceuticals Inc, SynCore Biotechnology Co Ltd, Taiho Oncology Inc, Tyme Inc; Data and Safety Monitoring Board/Committee: ASLAN Pharmaceuticals, Blueprint Medicines, Erytech; Speakers Bureau: Advanced Accelerator Applications, Celgene Corporation, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Novartis.
  
  Hope S Rugo, MD
  Professor of Medicine
  Director, Breast Oncology and Clinical Trials Education
  University of California, San Francisco
  Helen Diller Family Comprehensive Cancer Center
  San Francisco, California
  
  Consulting Agreements: Puma Biotechnology Inc, Samsung Bioepis; Contracted Research: Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seagen Inc; Paid Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, MacroGenics Inc, Merck, Mylan NV, Novartis, Pfizer Inc.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.
  
  Release date: December 2020
  Expiration date: December 2021
  
  After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.